drugset
Drugs / Recombinant methionyl human leptin
last change May 2010 re-read 3 minutes ago

Recombinant methionyl human leptin

Protein / enzyme biologic

Developed for
abdominal obesity-metabolic syndrome · diabetes mellitus · obesity disorder
Investigated by
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · University of Miami

Trials 2

today NCT00659828 · Ph 2 NCT00657605 · Ph 2
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00659828 Jun 2005 → Apr 2010 abdominal obesity-metabolic syndrome, diabetes mellitus, obesity disorder University of Miami Completed No outcome recorded
Phase 2 NCT00657605 Jun 2001 → May 2010 abdominal obesity-metabolic syndrome, diabetes mellitus, obesity disorder University of Miami Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Recombinant methionyl human leptin ClinicalTrials.gov intervention name — accepted as the source's own label NCT00659828 ↗
1

NCT00657605 ↗
Action Restore “Leptin replacement to three adults with this mutation normalized body weight and eating behavior.” PMID 17986612 ↗ Nov 2007
Modality Protein / enzyme biologic “the only bioactive leptin to which they will be exposed is the exogenously administered recombinant protein” NCT00657605 ↗
Route Subcutaneous “Recombinant methionyl human leptin, subcutaneous” NCT00657605 ↗